✦ LIBER ✦

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

✍ Scribed by Hope S. Rugo, A. Jo Chien, Sandra X. Franco, Alison T. Stopeck, Alexa Glencer, Soumi Lahiri, Michael C. Arbushites, Janet Scott, John W. Park, Clifford Hudis, Ben Nulsen, Maura N. Dickler

Book ID: 113062376
Publisher: Springer US
Year: 2011
Tongue: English
Weight: 271 KB
Volume: 134
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-011-1918-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination docetaxel and trastuzumab tr

Combination docetaxel and trastuzumab treatment for patients with her-2-overexpressing metastatic breast cancer: A multicenter, phase-II study

✍ Nobuaki Sato; Muneaki Sano; Toshio Tabei; Taro Asaga; Jiro Ando; Hirofumi Fujii; 📂 Article 📅 2006 🏛 Springer Japan 🌐 English ⚖ 553 KB

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB

Phase II Study of Gemcitabine and Bevaci

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Rachel Borson; Graydon Harker; James Reeves; Thaddeus Beck; Steven Hager; Willia 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 387 KB

Lapatinib, a Dual ErbB-1/ErbB-2 Kinase I

Lapatinib, a Dual ErbB-1/ErbB-2 Kinase Inhibitor, in the Treatment of HER2-Overexpressing Locally Advanced and Metastatic Breast Cancer

✍ Susan R. Peck; Joyce A. O'Shaughnessy 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 95 KB

P101 A multicenter phase II study of Epi

P101 A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer

✍ M. De Tursi; C. Carella; E. Ricevuto; A. Gennari; C. Orlandini; A. Frassoldati; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A multicenter phase II study of epirubic

A multicenter phase II study of epirubicin with low-dose trastuzumab as a first line treatment in Her-2 overexpressing metastatic breast cancer: preliminary results

✍ M. Zilli; De Tursi; C. Carella; E. Ricevuto; P. Marchetti; A. Gennari; C. Orland 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 135 KB